Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desmopressin ODT for nocturia due to nocturnal polyuria and sleep quality
NL-OMON44260Phase 3Withdrawn
- Sponsor
- Ferring Pharmaceuticals
- Start
- Sep 2017
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of desmopressin in nocturnal polyuria (NP), sponsored by Ferring Pharmaceuticals. Planned start Sep 2017; status: withdrawn.
02
Drugs
desmopressin
03
Conditions
nocturnal polyuria (NP)
Beyond the preview
Go deeper on NL-OMON44260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44260.